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 Abstract    
Background: Carcinogenic products in the exhaled breath of cancer patients are of growing medical interest as 
they can serve as noninvasive disease markers. Breath analysis can be used as an alternative or complementary 
diagnostic tool in breast cancer patients who have a different pattern of chemical composition in their breath. This 
study aims to verify the existence of specific volatile organic compounds (VOCs) in the breath of breast cancer 
patients.
Methods: This prospective study included ten patients suffering from breast cancer and ten healthy pair-matched 
women. Breath samples of each member of the two respective groups were taken and scanned by gas chromato-
graphy/mass spectometry for the presence of volatile organic compounds such as alkanes, ketones, halogenated 
hydrocarbon, aldehydes, and esters. 
Results: The spectrum of VOCs differed significantly within the two groups. Five specific VOCs could be identified 
as typical discriminatory markers in the breath samples. Four VOCs were elevated in the healthy controls, one spe-
cific VOC was found to be elevated in women affected by breast cancer.
Conclusions: This pilot study revealed a specific VOC pattern using gas chromatography in the breath of breast 
cancer patients. Five specific breast cancer-VOCs were identified. At relatively low cost the identification of VOCs 
may be used to detect breast cancer. 
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Introduction
In	a	society	where	breast	cancer	is	a	leading	cause	of	cancer	
death,	early	detection	of	the	disease	in	women	at	risk	of	breast	
cancer	or	in	the	general	population	is	highly	desirable.	Annually,	
46.000	women	in	Germany	are	affected	and	17000	to	18000	die	
from	breast	cancer.	Breast	cancer	is	 the	most	frequent	kind	of	
malignancy	in	women,	causing	4%	of	deaths	in	females	[1].	
Early	 detection	 of	 the	 disease	 minimizes	 therapeutic	
intervention and reduces mortality	[2,3].	General	mammography	
screening	 is	 undoubtedly	 profoundly	 effective	 for	 secondary	
prevention	of	breast	cancer,	regardless,	it	generates	high	expenses.	
The	costs	are	estimated	at	70-130€	per	patient,	amounting	to	the	
annual	sum	of	over	100	million	€	in	Germany	[1].
Alternative or complementary strategies are needed to 
increase	the	diagnostic	accuracy	and/or	to	lower	the	expenses	of	
breast	cancer	detection.	
A	recent	study	showed	that	‘a	man’s	best	friend’,	 the	dog,	
may	in	fact	contribute	to	the	process	of	early	cancer	detection	
by	sniffing	patient	breath	[4].	The	authors	reported	that	ordinary	
trained	 household	 dogs	 achieved	 the	 sensitivity	 of	 0.88	 (95%	
CI,	0.75,	1.00)	and	the	specificity	of	0.98	(95%	CI,	0.90,	0.99)	in	
the	identification	of	patients	with	breast	cancer	[4].	The	authors	
postulate	the	identification	of	chemical	compounds	in	an	exhaled	
breath	 that	 are	 associated	 with	 the	 presence	 of	 cancer.	 The	
compounds	are	most	 likely	cancer-induced	metabolites.	These	
metabolites,	including	volatile	organic	compounds	(VOCs),	are	
important	biomarkers	of	inflammatory	and	oxidative	processes	
of	anthropogenic	and	biogenous	origin	[5-8].	
According	to	the	definition	of	the	WHO,	VOCs	are	volatile	
organics	classified	according	 to	 their	 retention	 time	(C6	-C16)	
and	boiling	point	(50°C	–	250°C).	Thus,	subsuming	a	group	of	
substances	including	molecules	with	different	physical,	chemical	
and	 toxicological	 attributes	 such	 as	 alkanes,	 alkenes,	 ketones,	
halogenated hydrocarbons, aldehydes, esters, unsaturated 
hydrocarbons,	 terpenes,	 siloxanes,	 alcohols	 and	 aromates.	
Exogenic	VOCs	can	be	found	in	indoor	air,	building	materials	
or	 electrical	 equipment	 [20].	 Endogenous	VOCs	 are	 produced	
by	 people	 or	 animals	 and	 released	 through	 exhalation.	 There	
is	 a	wide	 inter-individual	 variation	 in	 their	 composition.	Still,	
certain	core	VOCs	that	can	be	reproduced	in	the	exhaled	air	of	
individuals	can	be	found	[19].	
Thus,	the	difference	in	the	concentration	of	VOC	between	
individuals	with	and	without	cancer	is	the	assumed	explanation	
why	 dogs	 can	 sniff	 out	 cancer	 [4].	 There	 have	 been	 attempts	
to	copy	the	success	of	the	dogs	by	establishing	artificial	noses	
[8].	Artificial	noses	are	subtle	machines	using	a	nanocomposite	
array	 of	 different	 organic	 polymer	 sensors.	 Exposing	 the	
sensors	to	VOCs,	they	change	their	electrical	resistance	as	they	
swell	 (“smelling	 by	 swelling”-	mechanism)	 [7,8].	This	 change	
in	 resistance	 is	 then	 transcribed	 in	 an	algorithmic	analysis.	A	
perfect	artificial	olfactory	replacement	which	could	be	compared	
to	the	human	or	canine	olfactory	system	has,	however,	not	yet	
been	invented	[8].	
Breath	analysis	is	a	powerful	tool	to	detect	various	diseases	
[7,9-18].	 Breath	 is	 a	 complex	 aerosol	 containing	more	 than	 a	
thousand	 of	 different	 nonvolatile	 (dissolved	 in	 microdroplets)	
and	volatile	components	[7,19].	This	organic	composition	can	be	
used	as	a	reliable	diagnostic	source.	
Breath sample tests have been implemented in the diagnosis 
and	 management	 of	 asthma	 by	 measurement	 of	 the	 exhaled	
nitric	 oxide	 (NO)	 or	 identification	 of	 lactose	 intolerance	 by	
breath	 hydrogen	 (H2)	 analysis	 using	 gas	 chromatography	 [9].	
Helicobacter	 pylori	 infection	 is	 detected	 by	 using	 the	 urea	
breath	 test.	 In	 patients	with	 heart	 transplants,	 breath	 samples	
are	used	to	predict	tissue	rejections	and	may	replace	myocardial	
muscle	biopsies	[10].	Furthermore,	promising	breath	screening	
tests	 are	 evaluated	 in	 patients	 suffering	 from	 heart	 diseases,	
schizophrenia, rheumatoid arthritis, or preeclampsia and asthma 
and	COPD	maybe	recognized	early	[5,	28,	29,	30].	
Breath	samples	are	obtained	non-invasively	and	the	analysis	
is	inexpensive.
 Streszczenie  
Cel: Coraz bardziej rośnie zainteresowanie medycyny produktami karcinogenezy w wydychanym powietrzu 
pacjentów chorych na raka jako możliwych nieinwazyjnych markerów choroby. Analiza powietrza wydychanego 
może być wykorzystana jako alternatywne lub pomocnicze narzędzie w raku piersi u pacjentek, które mają odmienny 
skład chemiczny oddechu. Celem tego badania była weryfikacja obecności lotnych związków organicznych (VOCs) 
w wydychanym powietrzu pacjentek z rakiem piersi. 
Metoda: Przeprowadzono prospektywne badanie, do którego włączono 10 pacjentek cierpiących na raka 
piersi i 10 zdrowych dobranych do pary kobiet. Pobrano próbki wydychanego powietrza od każdego uczestnika 
badania i poddano gazowej chromatografii/spektrometrii masowej na obecność nastepujących lotnych związków 
organicznych: alkanów, ketonów, halogenowanych wodorowęglanów, aldehydów i estrów. 
Wyniki: Spektrum VOCs różniło się istotnie w obu grupach. Pięć specyficznych VOCs zdefiniowano jako typowe 
markery w wydychanych próbkach. Cztery VOCs były podwyższone w grupie kontrolnej, natomiast jeden specyficzny 
VOC był podwyższony w grupie kobiet z rakiem piersi.
Wnioski: To badanie pilotażowe, przy pomocy gazowej chromatografii, wykazało specyficzny wzór VOC w 
wydychanym powietrzu u pacjentek chorych na raka piersi. Zidentyfikowano pięć specyficznych dla raka piersi 
VOCs. Przy relatywnie niskich kosztach identyfikacja VOCs może być wykorzystana do wykrywania raka piersi.
 Słowa kluczowe: rak piersi / lotne związki organiczne / analiza oddechu / 
      / gazowa chromatografia / spektrometria masowa (GC/MS) / 
      / wczesna diagnostyka raka piersi / 
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Identification	of	VOCs	is	technically	rather	challenging	as	
VOCs	are	produced	in	the	range	of	nano-	and	picomolars.	The	
methods	of	collecting	the	air	samples	described	in	literature	are	
not	easily	transferable	to	an	everyday	clinical	setting.	
Clinical	 management,	 however,	 requires	 an	 optimized	
and	 easy	 technique	 to	 collect	 the	 air	 samples,	 preferably in a 
standardized	setting.
Our	 aim	 was	 to	 find	 certain	 specific	 ‘smellprints’	 in	 the	
breath	of	breast	cancer	patients	by	identifying	a	group	of	specific	
biomarkers	(VOCs)	using	a	simple	and	approved	method	of	the	
gas	 chromatography/mass	 spectrometry	 (GC-MS).	 We	 also	
wanted	to	verify	the	practicability	of	the	test	using	an	everyday	
clinical	setting	for	our	analysis.	
Methods
The	 procedures	 of	 the	 study	 received	 ethical	 approval	
from	the	 institutional	ethics	committee	 responsible	 for	human	
experimentation.	
This	 prospective	 study	 included	 two	 groups	 of	 women:	
10	 successive	patients	with	breast	 cancer	 and	10	healthy	pair-
matched	control	subjects.	All	patients	and	test	persons	gave	their	
written	informed	consent	to	participate	in	this	study.	The	controls	
had a mammography without pathological findings within the 
last	 six	 months	 before	 the	 testing.	 Women	 with	 concomitant	
medical	problems	were	excluded	from	the	study.
The	method	 used	 in	 this	 study	was	 based	 on	 three	 steps	
(Figure	1):	
sampling a •	 representative	amount	of	breath,
purification	and	cleansing	of	the	sample,•	
measurement	of	VOCs	concentrations.•	
Breath sampling
Preliminary tests were carried out in order to choose the 
most appropriate experimental setup using material with zero 
emission	rates.
We	 took	 breath	 samples	 of	 the	 patients	 in	 the	 morning	
before	the	operation	in	a	standardized	setting:	drinking,	eating,	
and brushing teeth were not allowed within the last eight hours 
before	sampling.	The	temperature	in	the	examination	room	was	
kept	constantly	at	24°C.	
We	collected	an	amount	of	1000	milliliters	of	the	exhaled	
alveolar	breath	from	each	study	member,	as	well	as	compartment	
air	samples	during	the	same	time	(Figure	2).	
A	chemically	inert	glass	container	with	a	capacity	of	1000	
ml	was	used	as	a	storage	medium	for	the	breath	samples	(Figure	
2&3).	
The	 glass	 container	 was	 connected	 to	 a	 Tenax	 test	 tube	
containing adsorption filter	polymers	to	collect	the	VOCs	(Fig.	
2&3).	 Conjoined	 with	 the	 tube	 was	 an	 automatic	 pump	 (Fig.	
2&3).	 The	 patients	 were	 asked	 to	 exhale	 through	 a	 custom-
built	 device	 connected	 to	 the	 glass	 container	 five	 times	 after	
discharging	 the	 air	 from	 the	 anatomical dead space	 (approx.	
300ml).	After	 collecting	 the	 breath	 in	 the	 glass	 container	 the	
connection between test tube and glass container was opened 
and the pump was switched on to draw the air into the test tube 
using	a	flow	rate	of	100ml/min.	Then	the	test	tube	was	sealed	at	
both	ends	and	transferred	for	laboratory	analysis.	Compartment	
air	samples	were	taken	in	an	identical	fashion.	
Figure 2. Collection of breath during 5 exhalations discharging the air from the 
anatomical dead space (approx. 300ml). 1: exhalation tube, 2: glass container, 3 and 
5 inert connection tubes, 4: absorbent, 6: pump.
Figure 3. Test person during breath sample.
Figure 1. Scheme of taking and analyzing the probes.
active breath
sampling
thermodesorption
splitting and analysing via 
gaschromatography/mass 
spectrometry
VOC-concentration
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VOC analysis
An internal standard is added to the samples to guarantee 
an	 exact	 analysis.	 The	 probes	 are	 cleansed	 with	 helium.	 The	
VOCs	 are	 separated	 from	 the	 samples	 by	 thermal	 desorption.	
During thermodesorption, the loaded tube is heated up in a 
thermodesorption	unit	starting	at	30°C,	heating	up	to	280°C	by	
60°/min,	maintaining	 this	 temperature	 for	 eight	minutes.	 The	
VOCs	are	now	dissolved	within	the	inert	carrier	gas	helium,	this	
being	 the	 ‘mobile	phase’	of	 the	system.	They	are	 then	flushed	
into	a	cold	trap	and	frozen	at	-80°C.	After	heating	up	the	cold	
trap	to	280°C	by	12°C/min,	the	substances	are	transferred	from	
the	 carrier	 gas	 to	 the	 gas	 chromatograph	 (GC)	 and	 adhere	 to	
its	 capillary	 column,	 the	 so-called	 ‘stationary	 phase’,	 which	
separates	the	molecules	from	each	other	at	different	temperatures	
and	allows	them	to	be	quantified	and	qualified	via	GC-MS.	
The	 interactions	 of	 dissolved	 VOCs	 with	 the	 stationary	
phase	 causes	 different	 compounds	 to	 elute	 at	 different	 times,	
respectively,	 called	 the	 retention	 time.	 The	 analysis	 of	 the	
differing	 boiling	 points	 and	 the	 comparison	 of	 the	 retention	
times	helps	to	identify	the	substances.	The	dispersed	substances	
pass	a	detector	in	the	gas	chromatograph	which	transfers	certain	
changes	 of	 the	 physical	 composition	 of	 the	 carrier	 gas	 into	
electrical	signals.	These	signals	are	transferred	to	a	computer	or	
recorder	interpreting	the	changes.	
By evaluating the peaks and ‘area under the curve’, the 
quality	and	the	quantity	can	be	described,	respectively.	
By	 adding	 the	method	 of	mass	 spectrometry	 one	 can	 not	
only	increase	the	accuracy	of	the	detection	but	also	find	minute	
amounts	of	substances.	Mass	spectrometry	does	not	analyze	the	
mass	of	particles	alone	but	the	mass-to-charge	ratio	by	generating	
a	 mass	 spectrum.	 The	 dispersed	 substances	 of	 the	 stationary	
phase	 in	 the	 GC	 are	 transferred	 to	 the	 MS.	 There	 they	 are	
ionized by the ion source	via	collisions.	Electrons	are	colliding	
with	the	molecules	to	be	analyzed	producing	ions.	These	fragile	
ions	collapse	building	smaller	fragments.	The	fragments	can	be	
analyzed	by	 their	mass-to-charge	 ratio.	The	detection	 limit	of	
the	method	is	1	µg/m³	for	the	substance	under	investigation.	
Values	of	 compartment	 air	 samples	were	 subtracted	 from	
breath	sample	values.	The	data	was	recorded	with	a	 relational 
database management system	and	analyzed	via	SPSS	(Version	
15.0)	 using	 the	 Kolmogorov-Smirnov	 test,	 Mann-Whitney	 U	
test,	t-test,	and	ROC	curve	analysis.	
Results
The	mean	age	of	patients	was	64.5	(41-73)	years,	the	mean	
body-mass-index	was	25.50	kg/m²	(19	–	36),	9/10	(90%)	patients	
were	postmenopausal.	The	mean	age	of	 the	healthy	women	 in	
the control group	was	58.5	(51-70)	years,	the	mean	body-mass-
index	 was	 26.30	 kg/m²	 (22	 –	 31),	 10/10	 (100%)	 women	 were	
postmenopausal.	 In	 all	 patients	 breast	 cancer	 was	 confirmed	
histologically:	invasive ductal carcinoma	(n=7),	invasive	lobular	
carcinoma	(n=2)	and	tubular	cancer	(n=1).	Cancer	stages	were:	
pT1a	(n=3),	pt1c	(n=4),	pT2	(n=3).	Two	patients	had	one	affected	
lymph	node,	respectively.	In	all	patients	the	disease	was	limited	
to	the	breast.	
Unspecific VOCs
Using	 the	 gas	 chromatography	 in	 combination	with	mass	
spectrometry,	 we	 found	 a	 total	 of	 109	 different	 VOCs	 and	 a	
variation	of	83	 to	100	different	volatile	organic	compounds	 in	
the	breath	of	patients	and	controls.	We	identified	various	VOCs	
belonging	to	different	classes	including	26	alkanes,	7	alkenes,	
4 ketones, 11 halogenated hydrocarbons, 11 aldehydes and 
alcohols,	 9	 esters,	 4	 unsaturated hydrocarbons,	 13	 terpenes,	
3	 siloxanes,	 and	21	 aromates.	The	 identified	VOCs	had	 either	
a	 negative	 (amount	 <	 0	 µg/m³)	 or	 positive	 alveolar	 gradient	
(amount	>	0	µg/m³).	Variances	differed	in	the	patients.	
Regarding the analyses	of	the	quantity	of	VOCs,	the	patients	
exhaled	more	alkanes	and	alkenes	when	compared	to	controls.	
Regarding other substances such as ketones, halogenated 
hydrocarbons, aldehydes, esters, unsaturated hydrocarbons, 
terpenes,	 siloxanes,	 alcohols,	 and	 aromates,	 the	 alveolar	
gradients	did	not	differ.
We	 found	a	broad distribution concerning range, median, 
and standard deviation	in	most	of	the	VOCs	(examples	are	given	
in	Figure	4).
Specific VOCs
Among	all	 the	 substances	 tested,	five	VOCs	belonging	 to	
the alkanes, alkenes, halogenated hydrocarbons, aromates, or 
Figure 4. Boxplots of exemplary unspecific VOCs in µg/m³, ranges do not differ significantly within the two groups.
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terpenes	were	 found	 to	 be	 significantly	 different	 in	 the	 group	
of	 breast	 cancer	 patients	 using	 the	 t-test	 and	 Mann-Whitney	
U	 test.	 The	 five	 identified	 substances	 were:	 3-methylhexane,	
decene, caryophyllene, naphthalene,	 and	 trichlorethylene.	
Trichlorethylene	alone	was	significantly	elevated	in	the	group	of	
breast	cancer	patients	and	showed	a	positive	alveolar	gradient.	
The	 values	 of	 3-Methylhexane,	 decene,	 caryophyllene,	 and	
naphthalene	 were	 significantly	 decreased	 in	 the	 patient	 group	
and,	 except	 for	 naphthalene,	 all	 presented	 a	 negative	 alveolar	
gradient.	(Table	I).	
Discussion
There	is	increasing	evidence	that	searching	for	biomarkers	
by analyzing breath has an important place, not only in the 
clinical	 management	 of	 patients	 with	 pulmonary	 diseases	 [5,	
26].	Dogs	achieved	an	impressive	accuracy	when	exposed	to	the	
smell	of	patients	with	lung	or	breast	cancer	[4].
Inspired	 by	 these	 recent	 findings,	 breath	 sample	 analysis	
for	 detection	 of	 women	 with	 early	 breast	 cancer	 has	 become	
an	 important	 goal.	 A	 non-invasive	 parameter	 with	 adequate	
accuracy	could	replace	invasive	diagnostic	methods.	However,	
until	 now	 a	 perfect	 artificial	 olfactory	 system	 replacing	 the	
human	or	canine	olfactory	system	has	not	yet	been	found	[8].	
Thus,	 our	 study	 aimed	 at	 copying	 the	 canine	 nose	 and	
identifying	certain	specific	‘smellprints’	in	the	breath	of	breast	
cancer patients by using a simple and approved method such as 
the	GC-MS.	
The	questions	what	kind	of	mechanism	underlies	the	method	
of	breath	analysis	and	why	VOC	concentrations	differ	between	
healthy	individuals	and	individuals	with	diseases	remain.	Some	
VOCs	have	a	positive	alveolar	gradient,	others	a	negative	one.	
Phillips	 et	 al.,	 defined	 the	 expression	 ‘alveolar	 gradient’	 as	
abundance	of	VOC	in	breath	minus	abundance	in	air	[10,16,19,	
21].	 The	 polarity	 of	 the	 alveolar	 gradient	 appears	 to	 depend	
mainly	on	whether	a	VOC	originates	from	inside	or	outside	the	
body	 [23].	When	 the	 alveolar	 gradient	 is	 negative	 the	 rate	 of	
clearance	is	increased.	Most	volatile	substances	have	a	negative	
alveolar gradient in lung cancer patients and a positive alveolar 
gradient	 in	 healthy	 subjects	 because	 of	 the	 enhanced	 activity	
of	 cytochrome	P	450	due	 to	 oxidative	 stress.	Oxidative	 stress	
is	 induced	 by	 an	 overbalance	 of	 reactive	 oxygen	 species	 and 
oxygen	radicals	in	the	mitochondria	and	peroxisomes	of	tumor	
cells	 subsequently	 eluding	 into	 cytoplasm	 [24,	 25,	 27].	 There	
they	 oxygenate	 and	 damage	 not	 only	 the	DNA	and	 important	
proteins, but also polyunsaturated fatty acids, that are being 
converted	into	alkanes	and	methyl	alkanes,	e.g.	these	substances	
are	mainly	eliminated	via	the	lung	itself	or	metabolized	via	the	
enhanced	activity	of	the	cytochrome	P450	of	the	lung	[16,	21,	27].	
As	their	quantity	changes	with	the	amount	of	oxidative	stress,	
they	 can	 be	 traced	 in	 the	 breath.	 Oxidative	 stress,	 however,	
can	 be	 caused	 by	 other	mechanisms	 such	 as	 inflammation	 or	
infection	which	may	bias	the	results.
Studies	to	distinguish	between	early	and	late	stage	of	lung	
cancer	were	unsuccessful	[16,	21].	This	finding	could	also	serve	
as	evidence	that	the	different	pattern	of	VOCs	is	mainly	induced	
indirectly	by	the	enhanced	activity	of	cytochrome	P	450	in	cancer	
patients	and	not	by	the	tumor	metabolites	themselves.	Detecting	
the	enhancement	of	cytochrome	P450	as	an	early	consequence	
of	tumor	metabolism,	could	be	an	adequate	method	to	diagnose	
cancer.	Nevertheless,	 the	 enhancement	of	 cytochrome	P450	 is	
not	the	only	explanation	why	an	alteration	of	certain	VOCs	can	
be	reproduced	in	affected	patients.	Direct	interaction	of	tumor	
metabolites	in	cells	also	results	in	altered	(higher	or	lower)	levels	
of	 certain	 VOCs.	 Tumor	 cells	 produce	 different	 metabolites	
leading	 to	 increased	 levels	of	benzol	and	alkaline	derivates	 in	
the	affected	tissues,	 the	 latter	being	mainly	eliminated	via	 the	
exhalation	or	via	the	enhanced	activity	of	cytochrome	P	450	in	
the	lung	[21,	22,	26].	
The	 change	 of	 VOC	 pattern	may	 already	 be	 traceable	 in	
early	 stages	 of	 breast	 cancer	when	 histological	 detection	 fails	
[21].	 Phillips	 et	 al.,	 identified	 nine	 substances	 to	 trace	 lung	
cancer and eight substances to detect breast cancer, Diana Poli 
et	 al.,	 proclaimed	 13	 substances	 with	 significantly	 changed	
concentrations	 in	 patients	 with	 lung	 cancer	 differing	 from	
Phillips’	results	[21,	15].	Various	other	studies	showed	different	
significant	 patterns	 of	VOCs	 and	 only	 singular	matches	were	
shown	[13,	15,	17,	18,	21].	We	scanned	our	breath	samples	 for	
109	 substances	 in	 total	 including	 the	 substances	 identified	 in	
literature.
We	did	find	a	significant	alteration	of	the	concentration	of	
five	 specific	 VOCs:	 3-methylhexane,	 decene,	 caryophyllene,	
naphthalene,	 and	 trichlorethylene.	 The	 decrease	 in	 the	
concentration	 of	 3-methylhexane,	 decene,	 caryophyllene,	 and	
naphthalene	 in	 our	 breast	 cancer	 patients	 can	 result	 from	 the	
altered	 activity	 of	 cytochrome	 P	 450,	 whereas	 the	 increase	
of	 trichlorethylene	 might	 derive	 directly	 from	 tumor	 cell	
metabolites.	 Our	 findings	 do	 support	 the	 possible role of 
application	 for	breath	analysis	 in	cancer	patients.	 In	a	clinical	
everyday	 setting	 the	 relevance	 and	 reproducibility	 of	 VOC	
analysis	could	be	confirmed.	
In	 our	 study	 we	 could	 neither	 reproduce	 the	 specific	
alterations	of	biomarkers	found	in	Phillips’	breast	cancer	group	
nor	 those	of	 other	 cancer	 studies	 [21].	These	 results	 point	 out	
the	 fragility	 of	VOC	analysis.	Exact	 pathogenesis	 of	VOCs	 is	
unknown,	nutrition	might	have	an	impact	on	the	exhaled	pattern	
of	VOC	and	age	does	increase	the	quantity	of	VOCs	[22].	
Different	methods	 to	 analyze	 the	 breath	 samples	may	 be	
found	 [6,	 13].	 In	 recent	 investigations	 technical	 problems	 of	
sampling	and	analysis	occurred	and,	due	to	lack	of	normalization	
and	 standardization,	 great	 variations	were	 found	 between	 the	
results	of	different	studies	[11].	
Out	of	the	described	techniques	GC/MS	linking	fulfils	the 
best qualifications	to	identify	and	quantify	the	smallest	traces	of	
volatile	compounds	[6,	13].	Therefore,	we	chose	GC/	MS	as	it	is	the	
most	approved	method	with	the	best	results.	
We	scanned	our	breath	probes	for	almost	all	VOCs	identified	
in	 cancer	 patients	 so	 far,	 but	we	 found	 no	 consistency	 in	 the	
existing	data.	Looking	at	a	set	of	volatile	markers	may	enable	
recognition	and	diagnosis	of	patients	with	breast	cancer	in	the	
near	future	but	nevertheless,	extensive	research	has	to	be	done.
Conclusion
In an everyday clinical setting breath analysis can be 
implemented	 as	 an	 extra	 tool	 in	 breast	 cancer	 diagnosis.	We	
found	a	significantly	different	pattern	of	VOCs	in	the	breath	of	
breast	cancer	patients	when	compared	to	healthy	controls.	Still,	
further	and	multi-center	studies	need	to	be	performed	to	verify	
the	reproducibility	of	breath	analysis	in	breast	cancer	patients.
©  P o l s k i e  T o w a r z y s t w o  G i n e k o l o g i c z n eNr 10/2012 735
P R A C E  O R Y G I N A L N E
  g in eko l og ia 
Ginekol Pol. 2012, 83, 730-736   
Mangler M, et al. Volatile organic compounds (VOCs) in exhaled breath of patients with breast cancer in a clinical setting.
Table  I .  Cut off values after ROC curveanalysis.
©  P o l s k i e  T o w a r z y s t w o  G i n e k o l o g i c z n e Nr 10/2012736
P R A C E  O R Y G I N A L N E
  g in eko l og ia
Ginekol Pol. 2012, 83, 730-736 
Mangler M, et al. Volatile organic compounds (VOCs) in exhaled breath of patients with breast cancer in a clinical setting.
Acknowledgements
The authors wish to express their gratitude to Dieter Marchl for running 
the GC/MS. Sincere thanks are given to all patients and test persons 
participating in this study. Written consent for publication was obtained from 
the test person in figure 3.
List of abbreviations
GC/MS  – gas chromatography/mass spectrometry
VOC   – volatile organic compounds
ROC curve  – receiver operating characteristic curve
Competing interests 
The authors declare that they have no competing interests.
Contributions of the authors
MM  – participated in the design of the study and helped with the acquisition of 
data, patients, analysis and interpretation of data; drafting the article and 
revising it critically for important intellectual content; and participated in 
the final approval of the version to be published. 
CF  – participated in the design of the study and helped with the acquisition of 
data, patients, analysis and interpretation of data; drafting the article and 
revising it critically for important intellectual content; and participated in 
the final approval of the version to be published. 
ML  – added substantial contributions to concept and design, revised it 
critically for important intellectual content; and participated in the final 
approval of the version to be published.
OS  – added substantial contributions to concept and design, revised it 
critically for important intellectual content; and participated in the final 
approval of the version to be published.
AS  – added substantial contributions to concept and design, revised it 
critically for important intellectual content; and participated in the final 
approval of the version to be published.
DS  – added substantial contributions to concept and design, revised it 
critically for important intellectual content; and participated in the final 
approval of the version to be published.
All authors read and approved the final manuscript.
References:
  1. Mammographie-Screening [http://www.aerztekammerbw.de/25/ressourcen/screening.pdf] 
  2. Planche K, Vinnicombe S. Breast imaging in the new era. Cancer Imaging. 2004, 4, 39-50.
  3. Becker N, Junkermann H. Benefit and Risk of Mammography Screening. Considerations from 
an Epidemiological Viewpoint. Dtsch Arztebl Int. 2008, 105, 131-136.
  4. McCulloch M, Jezierski T, Broffman M, [et al.]. Diagnostic accuracy of canine scent detection in 
early- and late-stage lung and breast cancers. Integr Cancer Ther. 2006, 5, 30-39.
  5. Kharitonov S, Barnes P. Exhaled biomarkers. Chest. 2006, 130, 1541-1546. 
  6. Chen H, Wortmann A, Zhang W, Zenobi R. Rapid in vivo fingerprinting of nonvolatile compounds 
in breath by extractive electrospray ionization quadrupole time-of-flight mass spectrometry. 
Angew Chem Int Ed Engl. 2007, 46, 580-583.
  7. Dragonieri S, Schot R, Mertens B, [et al.]. An electronic nose in the discrimination of patients 
with asthma and controls. J Allergy Clin Immunol. 2007, 120, 856-862. 
  8. Lewis N. Comparisons between mammalian and artificial olfaction based on arrays of carbon 
black-polymer composite vapor detectors. Acc Chem Res. 2004, 37, 663-672.
  9. Lembcke B, Kirchhoff S, Caspary W. Simplified methods of expiratory hydrogen (H2) analysis--
clinical testing of two H2 breath test devices. Z Gastroenterol. 1983, 21, 545-549. 
10. Phillips M, Boehmer J, Cataneo R, [et al.]. Prediction of heart transplant rejection with a breath 
test for markers of oxidative stress. Am J Cardiol. 2004, 94, 1593-1594.
11. Miekisch W, Schubert J, Noeldge-Schomburg G. Diagnostic potential of breath analysis--focus 
on volatile organic compounds. Clin Chim Acta. 2004, 347, 25-39.
12. Barker M, Hengst M, Schmid J, [et al.]. Koppmann Volatile organic compounds in the exhaled 
breath of young patients with cystic fibrosis. Eur Respir J. 2006, 27, 929–936.
13. Chen X, Xu F, Wang Y, [et al.]. A study of the volatile organic compounds exhaled by lung cancer 
cells in vitro for breath diagnosis. Cancer. 2007, 110, 835-844. 
14. Buszewski B, Kesy M, Ligor T, Amann A. Human exhaled air analytics: biomarkers of diseases. 
Biomed Chromatogr. 2007, 21, 553-566. 
15. Poli D, Carbognani P, Corradi M, [et al.]. Exhaled volatile organic compounds in patients with 
non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res. 
2005, 6, 71. 
16. Phillips M, Gleeson K, Hughes J, [et al.]. Volatile organic compounds in breath as markers of 
lung cancer: a cross-sectional study. Lancet. 1999, 353, 1930-1933. 
17. Bleda-Iniesta C, de Castro Carpeño J, Carrasco J, [et al.]. New screening method for lung 
cancer by detecting volatile organic compounds in breath. Clin Transl Oncol. 2007, 9, 364-
368.
18. Rieder J, Lirk P, Ebenbichler C, [et al.]. Analysis of volatile organic compounds: possible 
applications in metabolic disorders and cancer screening. Wien Klin Wochenschr. 2001, 113, 
181-185. 
19. Phillips M, Herrera J, Krishnan S, [et al.]. Variation in volatile organic compounds in the breath of 
normal humans. J Chromatogr B Biomed Sci Appl. 1999, 729, 75-88. 
20. Schleibinger H, Laussmann D, Brattig C, [et al.]. Emission patterns and emission rates of MVOC 
and the possibility for predicting hidden mold damage? Indoor Air. 2005, 5, Suppl 9, 98-104.
21. Phillips M, Cataneo R, Ditkoff B, [et al.]. Volatile markers of breast cancer in the breath. Breast 
J. 2003, 9, 184-191.
22. Phillips M, Cataneo R, Greenberg J, [et al.]. Increased oxidative stress in younger as well as in 
older humans. Clin Chim Acta. 2003, 328, 83-86.
23. Phillips M, Greenberg J, Awad J. Metabolic and environmental origins of volatile organic 
compounds in breath. J Clin Pathol. 1994, 47, 1052-1053.
24. Deshpande V, Kehrer J. Oxidative stress-driven mechanisms of nordihydroguaiaretic acid-
induced apoptosis in FL5.12 cells. Toxicol Appl Pharmacol. 2006, 214, 230-236. 
25. Thomas R, Roy D. Mitochondrial enzyme-catalyzed oxidation and reduction reactions of stilbene 
estrogen. Carcinogenesis. 1995, 16, 891-895. 
26. Paoletti P. Application of biomarkers in population studies for respiratory non-malignant diseases. 
Toxicology. 1995, 101, 99-105. Review.
27. Hietanen E, Bartsch H, Béréziat J, [et al.]. Diet and oxidative stress in breast, colon and prostate 
cancer patients: a case-control study. Eur J Clin Nutr. 1994, 48, 575-586.
28. Weitz Z, Birnbaum A, Sobotka P, [et al.]. High breath pentane concentrations during acute 
myocardial infarction. Lancet. 1991, 337, 933-935. 
29. Humad S, Zarling E, Clapper M, Skosey J. Breath pentane excretion as a marker of disease 
activity in rheumatoid arthritis. Free Radic Res Commun. 1988, 5, 101-106.
30. Moretti M, Phillips M, Abouzeid A, [et al.]. Increased breath markers of oxidative stress in normal 
pregnancy and in preeclampsia. Am J Obstet Gynecol. 2004, 190, 1184-1190. 
